A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

被引：2
|
作者：
Andre, F. [1 ]
Kaufman, B. [2 ]
Juric, D. [3 ]
Ciruelos, E. [4 ]
Iwata, H. [5 ]
Mayer, I. A. [6 ]
Conte, P. [7 ]
Rugo, H. S. [8 ]
Loibl, S. [9 ]
Rubovszky, G. [10 ,11 ]
Tesch, H. [12 ]
Inoue, K. [13 ]
Lu, Y-S. [14 ]
Ryvo, L. [15 ]
Longin, A-S. [16 ]
Mills, D. [16 ,17 ]
Wilke, C. [17 ]
Germa, C. [18 ]
Campone, M. [19 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France
[2] Chaim Sheba Med Ctr, Breast Canc Unit, Ramat Gan, Israel
[3] Massachusetts Gen Hosp, Termeer Ctr Targeted Therapies, Boston, MA 02114 USA
[4] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[5] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[6] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[7] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy
[8] Univ Calif San Francisco, Ctr Comprehens Canc, Med Hematol Oncol, San Francisco, CA 94143 USA
[9] German Breast Grp, Med & Res, Neu Isenburg, Germany
[10] Natl Inst Oncol, Internal Med Oncol Div B, Budapest, Hungary
[11] Natl Inst Oncol, Dept Clin Pharmacol, Budapest, Hungary
[12] Ctr Hamatol & Onkol Bethanien, Dept Oncol, Frankfurt, Germany
[13] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Tel Aviv Sourasky Med Ctr Ichilov, Div Oncol, Tel Aviv, Israel
[16] Novartis Pharma SAS, Paris, France
[17] Novartis Pharma AG, Basel, Switzerland
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Ctr Rene Gauducheau, Med Oncol, Inst Cancerol Ouest Site, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Patrick Neven
    Hope S. Rugo
    Sara M. Tolaney
    Hiroji Iwata
    Masakazu Toi
    Matthew P. Goetz
    Peter A. Kaufman
    Yi Lu
    Nadine Haddad
    Karla C. Hurt
    George W. Sledge
    Breast Cancer Research, 23
  • [42] Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-)/hormone receptor-positive (HR plus ) breast cancer: A phase II, randomized, double blind, placebo-controlled study
    Andre, F.
    Neven, P.
    Musolino, A.
    Latini, L.
    Campone, M.
    Cortes, J.
    Barrios, C.
    Squires, M.
    Zhang, Y.
    Deudon, S.
    Gogov, S.
    Blackwell, K.
    CANCER RESEARCH, 2013, 73
  • [43] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [44] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [45] A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)
    Hurvitz, Sara A.
    Schilder, Jeanne Marie
    Frenzel, Martin
    Martin, Miguel
    CANCER RESEARCH, 2016, 76
  • [46] Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
    Omori, Yukie
    Enatsu, Sotaro
    Cai, Zhihong
    Ishiguro, Hiroshi
    BREAST CANCER, 2019, 26 (05) : 652 - 662
  • [47] Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
    Turner, Nicholas
    Oliveira, Mafalda
    Howell, Sacha J.
    Dalenc, Florence
    Cortes, Javier
    Gomez, Henry
    Hu, Xichun
    Jhaveri, Komal
    Loibl, Sibylle
    Murillo, Serafin Morales
    Nowecki, Zbigniew
    Okera, Meena
    Park, Yeon H.
    Toi, Masakazu
    Zhukova, Lyudmila
    Yan, Chris
    Schiavon, Gaia
    Foxley, Andrew
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
    Julie, Dejan
    Campone, Mario
    Munster, Pamela
    Ismail-Khan, Roohi
    Estevez, Laura Garcia
    Chavez-MacGregor, Mariana
    Frassoldati, Antonio
    Hui, Rina
    Mayer, Ingrid A.
    Cortes, Javier
    Goncalves, Anthony
    De Boer, Richard H.
    Dirix, Luc
    Tolaney, Sara M.
    Lee, Soo Chin
    Maur, Michela
    Wang, Yingbo
    Su, Faye
    Dobson, Jason R.
    Germa, Caroline
    Hewes, Becker
    Bardia, Aditya
    CANCER RESEARCH, 2017, 77
  • [49] Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB)
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Fasching, P. A.
    De Laurentiis, M.
    Im, S-A.
    Petrakova, K.
    Bianchi, G. V.
    Esteva, F. J.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Pivot, X.
    Sondhi, M.
    Wang, Y.
    Chakravartty, A.
    Rodriguez-Lorenc, K.
    Jerusalem, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Molecularly targeted therapy and immunotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer
    Song, Yuhua
    He, Lin
    Wang, Yaling
    Wu, Qian
    Huang, Wenzhi
    ONCOLOGY REPORTS, 2020, 44 (01) : 3 - 13
12345